132 related articles for article (PubMed ID: 12207113)
1. Gastric damage induced by subchronic administration of preferential cyclooxygenase-1 and cyclooxygenase-2 inhibitors in rats.
Villegas I; Alarcón de la Lastra C; Martín MJ; Motilva V; La Casa García C
Pharmacology; 2002 Oct; 66(2):68-75. PubMed ID: 12207113
[TBL] [Abstract][Full Text] [Related]
2. Mucosal damage induced by preferential COX-1 and COX-2 inhibitors: role of prostaglandins and inflammatory response.
Villegas I; La Casa C; de la Lastra CA; Motilva V; Herrerías JM; Martín MJ
Life Sci; 2004 Jan; 74(7):873-84. PubMed ID: 14659976
[TBL] [Abstract][Full Text] [Related]
3. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
5. Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam.
Berenguer B; Alarcón De La Lastra C; Motilva V; La Casa C; Herrerias JM; Pozo D; Calero MJ
Dig Dis Sci; 2004 Jun; 49(6):937-47. PubMed ID: 15309881
[TBL] [Abstract][Full Text] [Related]
6. Effects of food intake and oxidative stress on intestinal lesions caused by meloxicam and piroxicam in rats.
Villegas I; Alarcón de la Lastra C; La Casa C; Motilva V; Martín MJ
Eur J Pharmacol; 2001 Feb; 414(1):79-86. PubMed ID: 11230998
[TBL] [Abstract][Full Text] [Related]
7. Ischaemic colitis in a patient taking meloxicam.
Garcia B; Ramaholimihaso F; Diebold MD; Cadiot G; Thiéfin G
Lancet; 2001 Mar; 357(9257):690. PubMed ID: 11247558
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study.
Lipscomb GR; Wallis N; Armstrong G; Rees WD
Br J Clin Pharmacol; 1998 Aug; 46(2):133-7. PubMed ID: 9723821
[TBL] [Abstract][Full Text] [Related]
9. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
10. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
11. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
12. The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen, and piroxicam.
Jick SS
Pharmacotherapy; 2000 Jul; 20(7):741-4. PubMed ID: 10907963
[TBL] [Abstract][Full Text] [Related]
13. [Rheumatic disease therapy without regret. Meloxicam dosage safety].
MMW Fortschr Med; 2002 Nov; 144(46):66-7. PubMed ID: 12534086
[No Abstract] [Full Text] [Related]
14. [First i.m., now oral. COX-2 inhibitor in acute lumbago].
MMW Fortschr Med; 2002 Nov; 144(47):66. PubMed ID: 12532533
[No Abstract] [Full Text] [Related]
15. Chronic gastric ulcer healing in rats subjected to selective and non-selective cyclooxygenase-2 inhibitors.
Berenguer B; Alarcón de la Lastra C; Moreno FJ; Martín MJ
Eur J Pharmacol; 2002 May; 442(1-2):125-35. PubMed ID: 12020690
[TBL] [Abstract][Full Text] [Related]
16. Selective cyclooxygenase-2 inhibition prevents alveolar bone loss in experimental periodontitis in rats.
Bezerra MM; de Lima V; Alencar VB; Vieira IB; Brito GA; Ribeiro RA; Rocha FA
J Periodontol; 2000 Jun; 71(6):1009-14. PubMed ID: 10914805
[TBL] [Abstract][Full Text] [Related]
17. [Meloxicam (Mobic): a review of its pharmacological and clinical profile].
Ogino K; Saito K; Osugi T; Satoh H
Nihon Yakurigaku Zasshi; 2002 Dec; 120(6):391-7. PubMed ID: 12528470
[TBL] [Abstract][Full Text] [Related]
18. Melatonin protects against piroxicam-induced gastric ulceration.
Bandyopadhyay D; Ghosh G; Bandyopadhyay A; Reiter RJ
J Pineal Res; 2004 Apr; 36(3):195-203. PubMed ID: 15009511
[TBL] [Abstract][Full Text] [Related]
19. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation.
Wallace JL; Zamuner SR; McKnight W; Dicay M; Mencarelli A; del Soldato P; Fiorucci S
Am J Physiol Gastrointest Liver Physiol; 2004 Jan; 286(1):G76-81. PubMed ID: 14665439
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
